Company intelligence / Profile preview

ViroMasks

United Arab Emirates

Ownership: Private
Development stage: Other

Overview

ViroMasks commercializes reusable antiviral face masks powered by HeiQ Viroblock technology, shown in laboratory testing to inactivate 99.99% of SARS-CoV-2 virions on contact within 30 minutes. The masks, featuring a multi-layer filter similar to those used in N95/FFP2/KN95 standards, are designed for both public and healthcare use, with confirmed effectiveness for at least 20 washes.[2]

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Consumable Medical Devices

Partnerships

HeiQ (provider of HeiQ Viroblock technology)[2]

Beyond the preview

Go deeper on ViroMasks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroMasks.

Explore the full profile